Mind-NRG
About:
Mind-NRG develops peptidic neurotrophic factors for psychiatric and neurologic diseases.
Website: http://www.mind-nrg.com/
Top Investors: Index Ventures, Limburgse Reconversie Maatschappij
Description:
Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.
$23.7M
Geneva, Geneve, Switzerland
2010-01-01
info(AT)mind-nrg.com
Gage Tarrant
1-10
2013-09-04
Private
© 2025 bioDAO.ai